Aditxt Q3 plan: simplify cap table, cut debt, advance Adimune and Pearsanta

Aditxt, Inc.

CEO states goal is transition from speculative to growth stage by end of Q3 2025.
Short-term notes reduced from $8M to $3.5M; focus on paying down obligations.
Adimune progressing toward human trials; Pearsanta validating endometriosis and prostate cancer assays.
Pearsanta IPO uncertain due to weak market; timing depends on commercialization progress.
Company not at earnings stage; still raising capital; no near-term revenue or guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.